Ginkgo expects Cell Engineering services revenue of $165M-$185M in 2024 driven by expected growth in biopharma and government programs. This guidance excludes the impact of any potential downstream value share revenue. Ginkgo expects Biosecurity revenue in 2024 of at least $50M, representing approximate current contracted backlog, with potential upside from additional opportunities in the pipeline.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DNA:
- Ginkgo Bioworks acquires Proof Diagnostics, no terms disclosed
- Ginkgo Bioworks acquires Patch Biosciences, no terms disclosed
- Ginkgo Bioworks acquires key assets of Reverie Labs, no terms
- Ginkgo Bioworks Acquires Patch Biosciences, Expanding Suite of Genetic Medicine Capabilities Available to Customers
- Ginkgo Bioworks Acquires Proof Diagnostics, Growing Gene Editing Service Offerings for its Customers
